Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark
暂无分享,去创建一个
C. Sindet-Pedersen | J. Olesen | G. Gislason | E. Fosbøl | G. Lip | Jonas Bjerring Olesen | Gregory Y H Lip | Gunnar Hilmar Gislason | Emil Loldrup Fosbøl | Laila Staerk | Kasper Gadsbøll | Caroline Sindet-Pedersen | Anna Gundlund | L. Staerk | A. Gundlund | K. Gadsbøll | Kasper Gadsbøll | G. Gislason
[1] S. Lévy,et al. Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Heart Survey on Atrial Fibrillation. , 2007, Journal of the American College of Cardiology.
[2] M. Turakhia,et al. Oral Anticoagulant Therapy Prescription in Patients With Atrial Fibrillation Across the Spectrum of Stroke Risk: Insights From the NCDR PINNACLE Registry. , 2016, JAMA cardiology.
[3] Gerhard Hindricks,et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[4] Apixaban versus Warfarin in Patients with Atrial Fibrillation , 2012 .
[5] W. Nelson,et al. International Normalized Ratio Stability in Warfarin-Experienced Patients with Nonvalvular Atrial Fibrillation , 2015, American Journal of Cardiovascular Drugs.
[6] C. Pedersen,et al. The Danish Civil Registration System , 2011, Scandinavian journal of public health.
[7] J. Tolstrup,et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study , 2011, BMJ : British Medical Journal.
[8] P. Kirchhof,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[9] M. Ezekowitz,et al. Gender in atrial fibrillation: Ten years later. , 2010, Gender medicine.
[10] M. Aguilar,et al. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.
[11] Gerhard Hindricks,et al. 2012 Focused Update of the ESC Guidelines for the Management of Atrial Fibrillation , 2013 .
[12] B. Gersh,et al. Provider Specialty and Atrial Fibrillation Treatment Strategies in United States Community Practice: Findings From the ORBIT‐AF Registry , 2013, Journal of the American Heart Association.
[13] G. Breithardt,et al. Oral anticoagulation use by patients with atrial fibrillation in Germany , 2012, Thrombosis and Haemostasis.
[14] P. Kirchhof,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.
[15] Leon Poller,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[16] D. Cook,et al. Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care , 2005, Heart.
[17] F. McAlister,et al. Why do patients with atrial fibrillation not receive warfarin? , 2000, Archives of internal medicine.
[18] G. Breithardt,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[19] P. Kirchhof,et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events—European Registry in Atrial Fibrillation (PREFER in AF) , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[20] H. Sørensen,et al. The Danish prescription registries. , 1997, Danish medical bulletin.
[21] D. Singer,et al. Gender Differences in the Risk of Ischemic Stroke and Peripheral Embolism in Atrial Fibrillation: The AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) Study , 2005, Circulation.
[22] P. Kirchhof,et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. , 2014, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[23] Jeroen J. Bax,et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. , 2012, European heart journal.
[24] Silvia G. Priori,et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text , 2006 .
[25] J. Tolstrup,et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study , 2011, Thrombosis and Haemostasis.
[26] Elsebeth Lynge,et al. The Danish National Patient Register , 2011, Scandinavian journal of public health.
[27] P. Wolf,et al. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.
[28] A. Belanger,et al. The Framingham study. , 1976, British medical journal.
[29] P. Vestergaard,et al. Trend in mortality after stroke with atrial fibrillation. , 2007, The American journal of medicine.
[30] R. Giugliano,et al. Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation. , 2016, Hematology/oncology clinics of North America.
[31] Jeroen J. Bax,et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[32] J. Hallas,et al. Use of sumatriptan in Denmark in 1994-5: an epidemiological analysis of nationwide prescription data. , 1997, British journal of clinical pharmacology.